Holen Sie sich die Stockscreener-App
0.583
10.00%
0.053
Handel nachbörslich:
.55
-0.033
-5.66%
Schlusskurs vom Vortag:
$0.53
Offen:
$0.53
24-Stunden-Volumen:
41,241
Relative Volume:
0.52
Marktkapitalisierung:
$9.03M
Einnahmen:
$2.82M
Nettoeinkommen (Verlust:
$-14.20M
KGV:
-0.6859
EPS:
-0.85
Netto-Cashflow:
$-15.13M
1W Leistung:
-8.89%
1M Leistung:
+4.20%
6M Leistung:
-28.02%
1J Leistung:
-40.63%
1-Tages-Spanne:
$0.51
$0.6498
1-Wochen-Bereich:
$0.45
$0.6498
52-Wochen-Spanne:
$0.45
$1.27
Talphera Inc Stock (TLPH) Company Profile
Firmenname
Talphera Inc
Sektor
Telefon
650-216-3500
Adresse
1850 GATEWAY DRIVE, SAN MATEO
Vergleichen Sie TLPH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TLPH
Talphera Inc
|
0.583 | 9.03M | 2.82M | -14.20M | -15.13M | -0.85 |
|
ZTS
Zoetis Inc
|
163.50 | 72.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.98 | 47.08B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.16 | 45.99B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.29 | 17.52B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
312.26 | 13.78B | 2.76B | 1.11B | 898.10M | 22.77 |
Talphera Inc Stock (TLPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2020-07-20 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2019-11-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-07-10 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-04-24 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-02-15 | Eingeleitet | Credit Suisse | Outperform |
| 2018-10-23 | Eingeleitet | B. Riley FBR | Buy |
| 2017-10-13 | Herabstufung | Jefferies | Buy → Hold |
| 2017-10-13 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-07-14 | Fortgesetzt | Jefferies | Buy |
| 2016-09-15 | Bestätigt | ROTH Capital | Buy |
| 2016-08-05 | Herabstufung | Stifel | Buy → Hold |
| 2015-10-30 | Hochstufung | Jefferies | Hold → Buy |
| 2015-10-05 | Bestätigt | ROTH Capital | Buy |
| 2015-09-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-07-10 | Fortgesetzt | ROTH Capital | Buy |
| 2015-05-06 | Bestätigt | Mizuho | Neutral |
| 2015-05-05 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-03-10 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-03-09 | Herabstufung | Mizuho | Buy → Neutral |
Alle ansehen
Talphera Inc Aktie (TLPH) Neueste Nachrichten
Talphera (NASDAQ:TLPH) Given Buy Rating at HC Wainwright - Defense World
Talphera, Inc. Earnings Call: Progress Amid Challenges - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy on Talphera stock, $6 target - Investing.com India
Talphera: Q4 Earnings Snapshot - CT Insider
Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights - Yahoo Finance
Talphera Reports 2024 Financial Results and Study Update - TipRanks
Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad - MSN
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus - Investing.com India
FDA approves Talphera’s reduced NEPHRO CRRT study size By Investing.com - Investing.com South Africa
TLPH stock touches 52-week low at $0.5 amid market challenges By Investing.com - Investing.com South Africa
TALPHERA, INC. SEC 10-K Report - TradingView
Talphera Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FDA approves Talphera’s reduced NEPHRO CRRT study size - Investing.com India
Talphera reports Q4 EPS (7c) vs. (25c) last year - TipRanks
FDA Green Light: Talphera Slashes Trial Size by 58% as Q4 Losses Drop 57% - Stock Titan
TLPH stock touches 52-week low at $0.5 amid market challenges - Investing.com
Talphera to Reduce Size of Renal Replacement Therapy Study, Enters Private Placement; Shares Fall - MarketScreener
Talphera Scores Major FDA Win: NEPHRO Study Size Slashed by 58% While Securing $14.8M Backing - Stock Titan
Earnings Outlook For Talphera - Benzinga
Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025 - Yahoo Finance
Talphera Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Talphera (TLPH) Expected to Announce Earnings on Wednesday - Defense World
Talphera chief medical officer Aslam Shakil purchases $6,038 in stock By Investing.com - Investing.com South Africa
Talphera chief medical officer Aslam Shakil purchases $6,038 in stock - Investing.com
Talphera (NASDAQ:TLPH) Stock Price Down 1.9% – Here’s What Happened - Armenian Reporter
Talphera Inc (NASDAQ: TLPH) Is On The Rise - Stocks Register
RODMAN&RENSHAW Upgrades Talphera (NASDAQ:TLPH) to Strong-Buy - Defense World
Rodman & Renshaw sets Talphera stock Buy rating, $4 target - MSN
Talphera (NASDAQ:TLPH) Receives “Buy” Rating from HC Wainwright - Defense World
FDA to review Talphera's request to amend NEPHRO study By Investing.com - Investing.com Canada
FDA to review Talphera’s request to amend NEPHRO study By Investing.com - Investing.com Nigeria
FDA to review Talphera's request to amend NEPHRO study - Investing.com
Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study - The Eastern Progress Online
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus By Investing.com - Investing.com Australia
TLPH stock touches 52-week low at $0.6 amid market shifts - Investing.com UK
TLPH stock touches 52-week low at $0.61 amid market challenges - Investing.com
Talphera faces Nasdaq delisting over share price rule - Investing.com
Talphera faces Nasdaq delisting over share price rule By Investing.com - Investing.com UK
Acelrx Announces Dsuvia® Milestone C Approval; Provides Revenue Guidance for the First Quarter 2020 - Marketscreener.com
Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024 - Kilgore News Herald
Talphera CEO Vincent J. Angotti acquires $3,199 in common stock - Investing.com
Talphera CEO Vincent J. Angotti acquires $3,199 in common stock By Investing.com - Investing.com UK
Talphera CEO Vincent J. Angotti buys $3,649 in company stock By Investing.com - Investing.com Canada
Talphera CFO Raffi Asadorian sells shares worth $118 - Investing.com India
Talphera CEO Vincent J. Angotti buys $3,649 in company stock - Investing.com India
Talphera CFO Raffi Asadorian sells shares worth $118 By Investing.com - Investing.com Canada
Talphera Third Quarter 2024 Earnings: US$0.13 loss per share (vs US$0.085 loss in 3Q 2023) - Yahoo Finance
Talphera (FRA:R5XA) Inventories, Raw Materials & Components : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
Talphera Inc (TLPH) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - Yahoo Finance
Finanzdaten der Talphera Inc-Aktie (TLPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.06%
0.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):